It sounds like the question is: "After first-line VRd and second-line Dara-Poma-Dex, what third-line options might be available?"
By the third line, the myeloma has relapsed twice. Doctors look at a few key factors to decide what comes next:
- Which drugs the myeloma hasn't become resistant to
- How long the last Show Full Answer
It sounds like the question is: "After first-line VRd and second-line Dara-Poma-Dex, what third-line options might be available?"
By the third line, the myeloma has relapsed twice. Doctors look at a few key factors to decide what comes next:
- Which drugs the myeloma hasn't become resistant to
- How long the last remission lasted
- Overall health and how well previous treatments were tolerated Since both lenalidomide (VRd) and daratumumab + pomalidomide have already been used, the myeloma may be resistant to those. Doctors would likely pivot to combinations built around drugs not yet tried or still effective.
Some possible directions at third line could include:
- Carfilzomib-based combos (e.g., carfilzomib + dexamethasone), since bortezomib was used but carfilzomib is a different proteasome inhibitor
- Isatuximab-based combos, as an alternative to daratumumab
- CAR T-cell therapy (Abecma or Carvykti) if the myeloma is becoming harder to control
This is very individual, so a myeloma specialist is really the best person to map out the right path forward based on the full treatment history and current health status.
August 21
Join
Your Privacy Choices
